Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial
Domains
CancerOrigin | Files produced by the author(s) |
---|
_ |
Origin | Files produced by the author(s) |
---|
Accord Elsevier CCSD : Connect in order to contact the contributor
https://hal.science/hal-04548022
Submitted on : Friday, November 29, 2024-4:40:54 PM
Last modification on : Saturday, November 30, 2024-3:28:22 AM